Phaseline

Targets › ABCA4

ABCA4 (Retinal-specific phospholipid-transporting ATPase ABCA4): drug programs, companies and trials

4 programs from 4 companies in 4 trials: 4 Phase 1; Ophthalmology; next expected readout Dec 2026.

Flippase that catalyzes in an ATP-dependent manner the transport of retinal-phosphatidylethanolamine conjugates like 11-cis and all-trans isomers of N-retinylidene-phosphatidylethanolamine (N-Ret-PE) from the lumen to the cytoplasmic leaflet of photoreceptor outer segment disk membranes, where 11-cis-retinylidene-phosphatidylethanolamine is then isomerized to its all-trans isomer and reduced by RDH8 to produce…. (UniProt, P78363)

Open in Phaseline: the race on ABCA4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
West China HospitalJWK006
Adeno-associated virus vector expressing ABCA4 gene
ABCA4Phase 1Stargardt Disease 1Dec 2026
VeonGen TherapeuticsVG801
Gene therapy for ABCA4 mutation-associated retinal dystrophy
ABCA4Phase 1Retinal Dystrophy Due to Biallelic ABCA4 MutationsDec 2027
Ascidian TherapeuticsACDN-01
AAV-based vector carrying DNA construct encoding ABCA4 RNA exon editor
ABCA4Phase 1Stargardt DiseaseAug 2030
AAVantgarde Bio SrlAAVB-039
adeno-associated virus (AAV) gene therapy delivering ABCA4
ABCA4Phase 1Stargardt DiseaseJul 2032

Conditions

Stargardt Disease (2) Stargardt Disease 1 (1) Retinal Dystrophy Due to Biallelic ABCA4 Mutations (1)

Modalities

other (2), small molecule (2)

Companies

West China Hospital (1) VeonGen Therapeutics (1) Ascidian Therapeutics (1) AAVantgarde Bio Srl (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.